RADIOPHARMACEUTICALS (LUTATHERA and PLUVICTO)

The Medical Readiness Contracting Office-West of the Department of the Army has issued a notice of intent to award a sole source contract under solicitation number W81K0024R0020 to Advanced Accelerator Applications USA. This requirement supports the Department of Nuclear Medicine Service at Brooke Army Medical Center located at JBSA Ft Sam Houston, Texas. The contract involves the procurement of two manufacturer-specific radiopharmaceuticals classified under NAICS 325412 Pharmaceutical Preparation Manufacturing and PSC 6505 DRUGS AND BIOLOGICALS.

These FDA-approved products, Lutetium Lu-177 Dotatate (Lutathera) and Lutetium Lu-177 Vipivotide Tetraxetan (Pluvicto), are required for the imaging and treatment of somatostatin receptor-positive gastroeteropancreatic neuroendocrine tumors and adult patients with prostatic-specific membrane antigen-positive metastatic castration-resistant prostate cancer. The anticipated performance schedule includes five ordering periods beginning October 1, 2024, and concluding September 30, 2029. Annual quantities for Lutathera range from 30 to 31 units, while annual quantities for Pluvicto range from 108 to 140 units over the five-year period.

The response deadline for this notice is August 20, 2024, and Rosalba Martinez is the designated point of contact. Although this notice is not a request for quotations, the agency will consider capability statements from vendors that believe they can provide the stated supplies. This notice of intent identifies Advanced Accelerator Applications USA as the manufacturer of the required pharmaceuticals.